Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Modulation of NOX2 causes obesity-mediated atrial fibrillation
Arvind Sridhar, … , Jalees Rehman, Dawood Darbar
Arvind Sridhar, … , Jalees Rehman, Dawood Darbar
Published August 15, 2024
Citation Information: J Clin Invest. 2024;134(18):e175447. https://doi.org/10.1172/JCI175447.
View: Text | PDF
Research Article Cardiology

Modulation of NOX2 causes obesity-mediated atrial fibrillation

  • Text
  • PDF
Abstract

Obesity is linked to an increased risk of atrial fibrillation (AF) via increased oxidative stress. While NADPH oxidase 2 (NOX2), a major source of oxidative stress and reactive oxygen species (ROS) in the heart, predisposes to AF, the underlying mechanisms remain unclear. Here, we studied NOX2-mediated ROS production in obesity-mediated AF using Nox2-knockout mice and mature human induced pluripotent stem cell–derived atrial cardiomyocytes (hiPSC-aCMs). Diet-induced obesity (DIO) mice and hiPSC-aCMs treated with palmitic acid (PA) were infused with a NOX blocker (apocynin) and a NOX2-specific inhibitor, respectively. We showed that NOX2 inhibition normalized atrial action potential duration and abrogated obesity-mediated ion channel remodeling with reduced AF burden. Unbiased transcriptomics analysis revealed that NOX2 mediates atrial remodeling in obesity-mediated AF in DIO mice, PA-treated hiPSC-aCMs, and human atrial tissue from obese individuals by upregulation of paired-like homeodomain transcription factor 2 (PITX2). Furthermore, hiPSC-aCMs treated with hydrogen peroxide, a NOX2 surrogate, displayed increased PITX2 expression, establishing a mechanistic link between increased NOX2-mediated ROS production and modulation of PITX2. Our findings offer insights into possible mechanisms through which obesity triggers AF and support NOX2 inhibition as a potential novel prophylactic or adjunctive therapy for patients with obesity-mediated AF.

Authors

Arvind Sridhar, Jaime DeSantiago, Hanna Chen, Mahmud Arif Pavel, Olivia Ly, Asia Owais, Miles Barney, Jordan Jousma, Sarath Babu Nukala, Khaled Abdelhady, Malek Massad, Lona Ernst Rizkallah, Sang-Ging Ong, Jalees Rehman, Dawood Darbar

×

Figure 6

NOX2 inhibition in PA-treated hiPSC-aCMs using the NOX2 small-molecule inhibitor GSK-2795039 reverses obesity-induced ion channel remodeling.

Options: View larger image (or click on image) Download as PowerPoint
NOX2 inhibition in PA-treated hiPSC-aCMs using the NOX2 small-molecule i...
(A) Representative H2DCF staining of atrial cells from control, DIO, Nox2-KO, and DIO Nox2-KO mice. Scale bars: 20 μm. (B) Measured H2DCF fluorescence of atrial cells from control (n = 18 cells), DIO (n = 30 cells), Nox2-KO (n = 24 cells), and DIO Nox2-KO mice (n = 24 cells) at 0, 4, 8, and 12 minutes. (C) Rate of H2DCF increase in atrial cells from the 4 mouse groups. (D) Representative H2DCF staining of BSA-, PA-, and PA-GSK-hiPSC-aCMs. Scale bars: 50 μm. (E) Measured H2DCF fluorescence of BSA- (n = 22 cells), PA- (n = 26 cells), and PA-GSK-hiPSC-aCMs (n = 15 cells) at 0, 4, 8, and 12 minutes. (F) Rate of H2DCF increase in the 3 hiPSC-aCM groups. P > 0.05, *P < 0.05, ****P < 0.0001, by 2-tailed, unpaired Student’s t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts